The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer
Open Access
- 20 May 2010
- journal article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 10 (1), 220
- https://doi.org/10.1186/1471-2407-10-220
Abstract
Background Tumor microenvironment is composed of tumor cells, fibroblasts, endothelial cells, and infiltrating immune cells. Tumor-associated immune cells may inhibit or promote tumor growth and progression. This study was conducted to determine whether the number and microlocalization of macrophages, mature dendritic cells and cytotoxic T cells in non-small cell lung cancer are associated with patient's survival time. Methods Ninety-nine patients with non-small cell lung cancer (NSCLC) were included in this retrospective study. Paraffin-embedded NSCLC specimens and their clinicopathological data including up to 8-year follow-up information were used. Immunohistochemical staining for CD68 (marker for macrophages), CD83 (marker for mature dendritic cells), and CD8 (marker for cytotoxic T cells) was performed and evaluated in a blinded fashion. The numbers of immune cells in tumor islets and stroma, tumor islets, or tumor stroma were counted under a microscope. Correlation of the cell numbers and patient's survival time was analyzed using the Statistical Package for the Social Sciences (version 13.0). Results The numbers of macrophages, mature dendritic cells and cytotoxic T cells were significantly more in the tumor stroma than in the tumor islets. The number of macrophages in the tumor islets was positively associated with patient's survival time, whereas the number of macrophages in the tumor stroma was negatively associated with patient's survival time in both univariate and multivariate analyses. The number of mature dendritic cells in the tumor islets and stroma, tumor islets only, or tumor stroma only was positively associated with patient's survival time in a univariate analysis but not in a multivariate analysis. The number of cytotoxic T cells in the tumor islets and stroma was positively associated with patient's survival time in a univariate analysis but not in a multivariate analysis. The number of cytotoxic T cells in the tumor islets only or stroma only was not associated with patient's survival time. Conclusions The number of macrophages in the tumor islets or stroma is an independent predictor of survival time in NSCLC patients. Counting macrophages in the tumor islets or stroma is more useful in predicting patient's survival time than counting mature dendritic cells or cytotoxic T cells.Keywords
This publication has 28 references indexed in Scilit:
- The prognostic value of intraepithelial and stromal innate immune system cells in non‐small cell lung carcinomaHistopathology, 2009
- Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancerBMC Cancer, 2009
- Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survivalEuropean Respiratory Journal, 2009
- Long-Term Survival for Patients With Non–Small-Cell Lung Cancer With Intratumoral Lymphoid StructuresJournal of Clinical Oncology, 2008
- High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancerBritish Journal of Cancer, 2008
- Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinomaBritish Journal of Cancer, 2006
- Macrophage Polarization Comes of AgeImmunity, 2005
- Tumor-Associated Macrophages: The Double-Edged Sword in Cancer ProgressionJournal of Clinical Oncology, 2005
- Infiltrating immune cells, but not tumour cells, express FasL in non‐small cell lung cancer: No association with prognosis identified in 3‐year follow‐upInternational Journal of Cancer, 2002
- The origin and function of tumor-associated macrophagesImmunology Today, 1992